10-K/A: Stablecoin Development Corp. Restates 2025 Financials Due to Warrant Accounting Error

Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.) is restating its 2025 financial statements due to an accounting error related to common stock warrants, impacting warrant liability by $608.6 million.

Summary

• Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.) has filed an amendment to its 2025 Annual Report on Form 10-K to restate its financial statements for the year ended December 31, 2025.
• The restatement is due to an accounting error concerning the "October 2025 Pre-Funded Warrants," specifically the incorrect accounting for anti-dilution adjustment provisions.
• This error led to an understatement of the warrant liability by $608.6 million as of December 31, 2025, and a corresponding increase in the accumulated deficit.
• The company identified a material weakness in its internal control over financial reporting related to the review of contractual terms of equity-linked financial instruments.
• The company's legal name change to Stablecoin Development Corporation and its strategic repositioning as an on-chain holding company focused on protocol-aligned digital asset ecosystems became effective on April 2, 2026.
• The company completed a 1-for-5 reverse stock split on February 20, 2026.
• As of December 31, 2025, the company had $8.0 million in cash and cash equivalents.
• Management believes that available funds, including proceeds from a January 2026 private placement and ATM program, are sufficient to fund operations through at least March 19, 2027.
• The company divested its Avenova, PhaseOne, and DERMAdoctor businesses during 2024 and 2025, with their results presented as discontinued operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the material restatement of financial statements caused by an accounting error and the identification of a material weakness in internal controls, despite subsequent capital raises and a strategic pivot.

Positives

• The company has secured sufficient liquidity to fund operations through at least March 19, 2027, based on funds available as of December 31, 2025, and subsequent capital raises.
• The company has completed a strategic realignment, divesting legacy pharmaceutical businesses to focus on digital assets.
• Subsequent to year-end, the company raised significant capital through a January 2026 private placement and an ATM program, indicating investor confidence in the new strategy.
• The company's stock split, while not a financial positive, can improve liquidity and accessibility for investors.

Negatives

• A material weakness in internal controls over financial reporting was identified, leading to the restatement of financial statements.
• The restatement resulted in a significant increase in warrant liability ($608.6 million) and accumulated deficit.
• The company incurred a substantial net loss of $630.8 million for the year ended December 31, 2025, largely due to non-cash warrant-related losses.
• The company has a history of net losses and negative cash flows from operations.
• The company's reliance on digital assets exposes it to market price volatility and evolving regulatory frameworks.

Risks

• The material weakness in internal controls could continue to affect the company's ability to report financial results accurately and in a timely manner.
• The company's digital asset holdings are subject to significant price volatility and market dynamics.
• Evolving regulatory frameworks for digital assets could impose new compliance obligations or restrict certain activities.
• Future changes in stock ownership could result in additional ownership changes under Section 382 of the Internal Revenue Code, further limiting the utilization of net operating loss carryforwards.
• The company faces liquidity risk associated with converting digital asset holdings to cash or cash equivalents.
• A class action complaint was filed alleging breach of fiduciary duty related to disclosures in the definitive proxy statement for the January 2026 private placement.

Future Outlook

Management believes that the company's existing cash and cash equivalents, combined with proceeds from the January 2026 Private Placement and the 2026 ATM Program, will be sufficient to fund planned operating expenses at least through March 19, 2027. The company's strategy is focused on acquiring and holding digital assets.

Management Comments

• Management believes that the Company's existing cash and cash equivalents will be sufficient to fund its planned operating expenses at least through March 19, 2027.
• Management assessed the effectiveness of internal control over financial reporting as of December 31, 2025, and identified a material weakness.
• Management is committed to completing remediation as promptly as practicable to address the material weakness.

Industry Context

StockSavvy.ai notes that Stablecoin Development Corporation's strategic shift from its legacy pharmaceutical operations to a digital asset treasury company reflects a broader trend of companies exploring decentralized finance and blockchain technologies. The significant capital raised post-year-end, despite the restatement, indicates potential investor interest in this new direction, though the company's success will hinge on navigating the volatile digital asset market and evolving regulatory landscape.

Legal Proceedings

• A class action complaint was filed alleging breach of fiduciary duty related to claimed deficiencies in disclosures in the Definitive Proxy Statement for the January 2026 private placement. The company believes disclosures complied with law and has filed a motion to dismiss.

Related Party Transactions

• The issuance of October 2025 Pre-Funded Warrants to R01 Fund LP, which is managed by an entity where the CEO is the managing member, constituted a related party transaction.

Stakeholder Impact

• Shareholders are impacted by the restatement, which increases the accumulated deficit and reflects a material weakness in controls.
• Investors may be concerned about the company's ability to accurately report financial information due to the identified material weakness.
• The company's strategic shift to digital assets may impact future shareholder value depending on market performance and regulatory outcomes.

Next Steps

• Implement remediation measures to address the material weakness in internal controls.
• Continue to monitor and adjust strategy based on digital asset market trends and regulatory developments.
• The company's stockholders approved the issuance of shares upon exercise of January 2026 and October 2025 Pre-Funded Warrants.
• The company's stockholders approved an amendment to increase the authorized shares of common stock.

Key Dates

Recommendation

The company has undergone significant strategic changes and a financial restatement due to internal control weaknesses. While recent capital raises provide liquidity and signal investor interest in the digital asset strategy, the material weakness and substantial net losses warrant caution. A 'hold' recommendation is appropriate pending further evidence of improved financial controls and successful execution of the digital asset strategy.

Keywords

Stablecoin Development Corporation, NovaBay Pharmaceuticals, 10-K/A, SEC Filing, Restatement, Warrant Liability, Internal Controls, Digital Assets, SKY Tokens, Private Placement, ATM Program, Reverse Stock Split